Physicians' Academy for Cardiovascular Education
It has been 3 years since the presentation and publication of the REDUCE-IT trial. What are more recent insights from subsequent analyses of the REDUCE-IT trial?
ESC 2022 An analysis of the REDUCE-IT trial showed that use of icosapent ethyl reduces the rate of MI overall, and of MI subtypes including STEMI, NSTEMI, MI leading to cardiac arrest and resuscitated MI, when compared to placebo.
After presenting findings from the REDUCE-IT trial, prof. Packard discusses the place for icosapent ethyl. He talks about the need for a tailored approach in ASCVD patients with high risk.
NICE in the UK has published a final guidance on recommendation for use of icosapent ethyl in adult statin-treated patients with elevated triglycerides, well-controlled LDL-c and established CVD.
The REDUCE-IT trial showed that treatment with icosapent ethyl is effective in patients receiving a statin who meet certain biochemical criteria. The CAC score may help to identify patients who would benefit most from this treatment.
The National Institute for Health and Care Excellence (NICE) has published a final draft guidance which recommends use of icosapent ethyl in adults with CVD, statin-controlled LDL-c levels and elevated triglycerides.
Watch the videos in this series and learn about icosapent ethyl in relation to CV risk and its potential mechanisms of action!
In a subgroup analysis of REDUCE-IT, additional treatment with icosapent ethyl resulted in less ischemic events in statin-treated patients with prior MI.
Prof. Packard shares some thoughts on the potential mechanisms of benefit of icosapent ethyl as seen in the REDUCE-IT trial.
Watch a discussion by three experts on potential mechanisms, side effects, patient selection, parameters for monitoring and future studies with regard to icosapent ethyl.
What are key findings of two CV outcomes trials with icosapent ethyl? Prof. Jukema provides an overview and discusses remaining questions with regard to findings of REDUCE-IT. With poll.
There was no difference of icosapent ethyl efficacy among statin agents and statin categories (lipophilic vs. lipophobic statins) in an exploratory analysis of the REDUCE-IT trial.
